Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists
Add-back therapy in patients treated with GnRHa for endometriosis protected bone mineral density and collagen resorption but reduced GnRHa efficacy, despite both groups showing symptom improvement.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (18)
- A new treatment for endometriosis via openalex
- Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol via openalex
- Bone mineral density of the lumbar spine in endometriosis subjects compared to an age-similar control population via openalex
- Endometriosis, 1995--confusion or sense? via openalex
- Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain via openalex
- Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain via openalex
- Hormone treatment of endometriosis: the estrogen threshold hypothesis via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial via openalex
- [Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)] via openalex
- Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women via openalex
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment via openalex
- Steroidal 'add-back' therapy in patients treated with GnRH agonists via openalex
- The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl) via openalex
- W2287757320 via openalex
- W164119867 via openalex
- W1977603398 via openalex
- W2075980057 via openalex
- W2073025986 via openalex
Cited by (7)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Pathophysiological Basis of Endometriosis-Linked Stress Associated with Pain and Infertility: A Conceptual Review 2020
- Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone 2015
- Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis 2014
- Emerging Issues In Endometriosis 2005
- The effect of physical training on bone mineral density in women with endometriosis treated with GnRH analogs: a pilot study 2005
- Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density 2003
Source provenance
- europepmc
- last seen: 2026-10-15T06:08:49.021275+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T22:00:48.437354+00:00